INVE Technologies NV produces animal feed and engages in aquaculture. It provides nutrition and health products for fish and shellfish in hatcheries, farms, and feed mills; and additives and specialty ingredients for the agriculture and aquaculture feed industry. The company offers its products for the performance enhancement, preservation and stabilization, health and well-being, feed and food safety, and sensory improvement of poultry, pig, ruminant, aqua and pet species. INVE Technologies was founded in 1963 and is headquartered in Dendermonde, Belgium.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Unilever NV engages in the production and marketing of consumer goods in the nutrition, hygiene, and personal care categories. It operates through the following segments: Beauty and Personal Care, Foods and Refreshment, and Home Care. The Beauty and Personal Care segment covers the sales of skin and hair care products, deodorants and oral care products. The Foods and Refreshment segment includes the sales of soups, bouillons, sauces, snacks, mayonnaise, salad dressings, margarines and spreads. The Home Care segment is in charge of the sales of home care products such as powders, liquids and capsules, soap bars, and a wide range of cleaning products. The company was founded on November 9, 1927 and is headquartered in Rotterdam, Netherlands.

Professional Dietetics is a healthcare product developer. Professional Dietetics is committed to the discovery, development, approval, and marketing of foods for special medical purposes, food supplements, and medical devices. They identify and develop science-driven solutions to meet the needs of patients and doctors across a wide range of therapeutic areas and clinical indications.

Korea Research Institute of Bioscience and Biotechnology (KRIBB) is a government research institute in Daejeon, South Korea. It is dedicated to biotechnology research across a broad span of expertise, from basic studies for the fundamental understanding of life phenomena to applied studies such as drug discovery, novel biomaterials, integrated biotechnology and bioinformation.

Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. They help people with debilitating and complex conditions that are often difficult to diagnose and treat. They are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, they also established ourselves as a leader in the field of multiple sclerosis. In 2016, their focus expanded to include Sanofi’s programs in oncology and immunology. Their approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, they rapidly grew to become one of the world’s leading biotechnology companies, recognized for their pioneering development of treatments for rare genetic disorders and their innovative contributions to medical science and biomanufacturing.

Biocompatibles UK Ltd. is a company headquartered in Farnham, UK, that manufactures, and markets implantable products for patients. The firm was founded in 2001.

Part of Kuros Biosciences Ltd., Kuros Biosurgery AG is a Swiss company located in Schlieren. The firm engages in researching and developing biological & physical sciences.

Unilever Plc engages in the manufacture and sale of consumer goods. It operates through the following segments: Beauty & Wellbeing, Personal Care, Home Care, Nutrition, and Ice Cream. The Beauty & Wellbeing segment offers hair care, skin care, and prestige beauty and health & wellbeing. The Personal Care segment consists of sales of skin cleansing, deodorant, and oral care products. The Home Care segment comprises of sales of fabric care and a wide range of cleaning products. The Nutrition segment refers to sales of scratch cooking aids, dressings, and tea products. The Ice Cream segment covers primarily ice cream products. The company was founded by Antonius Johannes Jurgens, Samuel van den Bergh, and William Hulme Lever on January 1, 1930 and is headquartered in London, the United Kingdom.

CellSpect Co., Ltd. provides healthcare services that engages in the development of clinical diagnostic methods by sensing markers. The company was founded in April 2014 and is headquartered in Morioka, Japan.

Tianjin Haiyou Jiayin Biotechnology Co., Ltd., established on 1999-09-01, Business scope includes biotechnology development;Aquatic Feed Manufacturing,processing,Sales;Import and export business of self-operated products;Biological bait farming;Feed Processing Technology Consulting Service;Business Information Consulting Service;Chemical Products(Dangerous goods except flammable, explosive and precursor drugs),feed,Minerals(except coal)Wholesale and retail;aquaculture;Aquaculture Technical Consulting Services;Warehousing Services(except dangerous goods).(If the above business scope involves industry licensing, the license certificate,Operate within the validity period,If the country has special franchise regulations, it shall be handled in accordance with the regulations)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Pfizer Inc. (NYSE: PFE, /ˈfaɪzər/) is an American multinational pharmaceutical corporation headquartered in New York City was founded in 1849, based in New York City and was listed on New York Stock Exchange. It is one of the world's largest pharmaceutical companies. It is listed on the New York Stock Exchange, and its shares have been a component of the Dow Jones Industrial Average since 2004. Pfizer ranked No. 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue.

Seno Medical was formed to commercialize a new modality in cancer screening and diagnosis: opto-acoustic imaging. Unlike most screening techniques, which rely on anatomical imaging, Seno's goal is to bring functional imaging that can detect angiogenesis to the marketplace. Their first product is a small animal imaging device. This product application was successfully licensed to a world market leader, VisualSonics. Products for use with humans, focusing initially on breast cancer, are also in development. Seno’s first clinical application is for breast cancer diagnosis. A strong, experienced management team and nationally recognized Scientific Advisory Board have been assembled to complete the commercialization, secure regulatory approval and launch the products. The management team has a long history of working together and in successfully commercializing medical devices. Seno’s patented technology integrates the use of lasers and acoustics to determine the presence of angiogenesis—the growth of blood vessels and higher blood volume that always surrounds a tumor. This represents a significant evolutionary step in imaging. Unlike anatomical imaging techniques, such as mammography, laser opto-acoustic imaging can detect breast cancer, for example, at its earliest clinically significant stage (2 mm. versus 10 mm. with mammography) without patient discomfort or exposure to harmful x-ray. The opportunities are exciting…for investors and scientists, for physicians and the myriad women and men tested for or diagnosed with cancer each year. The goal of laser opto-acoustic imaging is to allow more precise and earlier detection of smaller tumors and the ability to differentiate benign from malignant growth without biopsy. Future applications will focus on other types of cancer and broader diagnostic and treatment applications. Seno acquired working pre-prototypes in addition to the core patents on opto-acoustic technology; they will license two other patents for future applications. These patents constitute a platform technology with a multitude of potential follow-on applications, including imaging for the earliest detection of cancer of the ovary, bladder, prostate, colon and melanoma as well as unstable plaque (cardiovascular). Peer review and the continued funding of $13 million from nationally recognized institutions such as the National Institutes of Health (NIH), National Cancer Institute (NCI) and the Department of Defense (DoD) support their scientific credibility. And, significantly, the pre-prototypes being used in clinical testing have demonstrated a strong correlation to biopsy in diagnosing cancer. They look forward to the future and to the role Seno can play in minimizing the uncertainty, the cost and trauma of diagnosing and treating cancer.

Aderans Research Institute primarily operates in the Biotechnical Research, Commercial business / industry within the Engineering, Accounting, Research, and Management Services sector. This organization has been operating for approximately 14 years. Aderans Research Institute is estimated to generate $4.3 million in annual revenues, and employs approximately 53 people at this single location.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Scios Inc. is a pharmaceutical company developing drugs for the treatment of cardiovascular and inflammatory diseases. The company is a subsidiary of Johnson & Johnson. The company’s portfolio of drugs includes NatrecorO, a promising drug for heart failure. Scios Inc. was founded in 1981 and is based in California.